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Introduction
In Fanconi anemia (FA) and Down syndrome (DS), 
chromosomal aberrations[1] and cancer proneness are 
hallmark features shared by these two disorders, as well as 
other manifestations including early aging, immunological 
dysfunction, and congenital malformations.[2]
Fanconi anemia (MIM 227650) is a rare autosomal recessive 
disorder featuring bone marrow failure, proneness to malignancies, 
and chromosomal instability.[3,4] FA is diagnosed by detection of 
excess chromosomal instability induced by diepoxybutane (DEB) 
or mitomycin C.[5,6] The high frequency of chromosomal breaks 
in FA has been related to the increased oxidative damage via the 
intermediacy of superoxide that stimulates further superoxide 
production. This long-lasting process may exceed the DNA repair 
system leading to progressive impairment of bone marrow and 
predisposing patients to leukemia.[7]
Down syndrome (MIM 190685) is caused by trisomy 21 
and the over-expression of the genes present on the extra 
chromosome 21. DS is the most common aneuploidy, 
occurring as frequently as approximately one in every 700 live 
births.[8,9] The evidence of increased oxidative stress in DS is 
strong and includes gene dose overexpression of superoxide 
dismutase (SOD), increased lipid peroxidation, and increased 
oxidative DNA damage. Oxidative stress may have a direct 
role in producing the neuropathology of DS.[10]
Oxidative Stress ‑a Phenotypic Hallmark of Fanconi 
Anemia and Down Syndrome: The Effect of 
Antioxidants
El‑Bassyouni HT, Afifi HH, Eid MM1, Kamal RM4, El‑Gebali HH4, El‑Saeed GSM2, 
Thomas MM, Abdel‑Maksoud SA3
Departments of Clinical Genetics, 1Human Cytogenetics, 2Medical Biochemistry and 3Clinical Pathology National Research Centre, 
4Institute of Postgraduate Childhood Studies, Ain Shams University, Cairo, Egypt
Abstract
Background: Oxidative stress plays a major role in the pathogenesis of leukemia‑prone 
diseases such as Fanconi anemia (FA) and Down syndrome (DS). Aim: To explore 
the oxidative stress state in children with DS and FA by estimating the levels of 
antioxidants (e.g., malondialdehyde [MDA], total antioxidant capacity, and superoxide 
dismutase [SOD] activity) and DNA damage, and to evaluate of the effect of antioxidant 
treatment on these patients. Subjects and Methods: The study included 32 children clinically 
diagnosed with (15 patients) and FA (17 patients) in addition to 17 controls matched 
for age and sex. MDA, total antioxidant capacity, SOD activity, and DNA damage were 
measured. Antioxidants including Vitamin A, E, and C were given to the patients according 
to the recommended daily allowance for 6 months. Clinical follow‑up and re‑evaluation were 
conducted for all patients. Laboratory tests including complete blood count, karyotyping, 
DNA damage, and oxidative stress were re‑evaluated. Statistical analysis was performed 
using statistical computer program Statistical Package for the Social Sciences version 14.0. 
Results: Children with FA and DS had elevated levels of oxidative stress and more DNA 
damage than controls. Oxidative stress parameters and DNA damage improved in FA and DS 
patients after antioxidant administration. Conclusion: Early administration of antioxidants 
to FA and DS patients is recommended for slowing of the disease course with symptoms 
amelioration and improvement of general health.
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Genome integrity in FA and DS has diagnostic and prognostic 
importance because of the evident relationship between genome 
instability and both DNA damage and cancer predisposition.[11] 
DNA damage is detected by Comet assay represented by an 
increase of DNA fragments that have migrated out of the cell 
nucleus in the form of a characteristic streak similar to the 
tail of a comet.[12]
Antioxidant administration plays an important role in 
improving the disease course by decreasing oxidative 
stress-associated complications. [2,13,14]
The aim of the study was to explore the oxidative stress 
state in children with DS and FA by estimating the levels 
of antioxidants (malondialdehyde (MDA), total antioxidant 
capacity and SOD activity) and DNA damage, and to evaluate 
the effect of antioxidant treatment on these patients.
Subjects and Methods
Patients enrolled in the study were selected randomly from 
patients referred to the outpatient clinic of the Clinical 
Genetics Department, NRC, Egypt and they were followed-up 
for 1½ years during 2012–2014. The patients’ ages ranged 
between 2 and 10 years. The study included 32 children 
clinically diagnosed as FA (group I: 17 patients), DS (group II: 
15 patients) in addition to 17 controls (group III) matched for 
age and sex. An informed consent was signed by the parents. 
The study was approved by the Ethical Committee of the 
National Research Centre.
Exclusion criteria
• Children (patients or controls) taking antioxidants or 
multivitamins containing antioxidants
• Transplanted FA patients.
All children enrolled in the study were subjected to:
I. Clinically:
• Full history taking
• Pedigree construction
• Thorough clinical examination of all body systems to 
detect any system abnormality
• Essential anthropometric measures[15]
II. Laboratory investigations at the start of the study:
• Complete blood count (CBC) for FA patients
• Cytogenetic study:
  • Conventional cytogenetic study[16]
  • Induction of chromosomal breakage by the DEB 
for FA patients to confirm the diagnosis of FA and to 
determine the degree of the chromosomal breakage 
before starting the antioxidant therapy[17,18]
• Comet assay: DNA damage was evaluated in leukocytes[19]
• Estimation of Oxidative stress parameters including:
  •  Thiobarbituric acid reactive species (MDA) as a 
marker of lipid peroxidation[20]
  •  Total antioxidant capacity biomarker[21]
  •  Superoxide dismutase biomarker as an antioxidant 
enzyme[22]
III. Antioxidants therapy: Including Vitamin A, E, and C were 
given to the patients according to the recommended daily 
allowance for 6 months. Vitamin A was given in a dose of 
4000 IU/day, Vitamin E in 10 mg/day, and Vitamin C in 
25 mg/day
IV. Clinical follow-up every month: All patients were clinically 
examined every month to assure their compliance to 
treatment and check for any complaints
V. Re-evaluation after 6 months of treatment:
•	 Clinical re-evaluation and essential anthropometric 
measurements were done for all patients
•	 Laboratory tests including CBC, evaluation of the 
DNA damage level was done by DEB test and comet 
assay and the values of oxidative stress were repeated 
to evaluate the effect of antioxidant therapy.
Statistical analysis
Statistical analysis was performed on IBM/PC using 
statistical computer program Statistical Package for the 
Social Sciences (SPSS) version 14.0 for windows (SPSS Inc. 
Chicago, USA). The tests used were descriptive test, Pearson’s 
correlation test (correlation coefficient r) to test a positive or 
negative linear relationship between two variables and simple 
t‑ test (p ‑ values < 0.05 were considered significant).
Results
Demographic and clinical features of FA patients (group I) are 
summarized in Table 1.
Oxidative stress parameters in FA patients revealed significantly 
higher MDA levels (P < 0.01) and non significantly lower 
total antioxidant capacity (TAC) and SOD levels than the 
Table 1: Clinical data of group I (Fanconi anemia)
Parameter Number Frequency (%)
Male/female 9/8 1.8/1
Positive parental consanguinity 15/17 88.2
Similarly affected family members 10/17 58.8
Epistaxis, petechiae, and ecchymosis 17/17 100
Skin hyperpigmentation 11/17 64.7
Short stature 11/17 64.7
Microcephaly 9/17 52.9
Underweight 6/17 35.3
Radial reduction defects 6/17 35.3
Respiratory disease 6/17 35.3
Renal disease 5/17 29.4
Hypopigmented areas 3/17 17.6
Congenital heart defect 3/17 17.6
GIT problems 2/17 14.3
Growth hormone deficiency 2/17 14.3
Eye affection 1/17 5
Gonadal affection 1/17 5
Simian creases 1/17 5
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controls (r = −0.5 and P = 0.02, respectively) denoting the 
effect of increased oxidative stress. Improvements of the 
studied oxidative stress parameters were detected after 
antioxidant administration with significant lowering of MDA 
levels (P < 0.01) and significant elevation in TAC (P < 0.01) 
and SOD levels (P < 0.01) [Table 2, Figure 1].
Fanconi anemia group of patients showed more significantly 
higher DEB-induced chromosomal breakage (P < 0.01) and 
more DNA damage (P < 0.01) than controls (P < 0.05). 
Significant improvements of DEB and DNA damage levels 
were detected after antioxidant administration [Figures 2-4].
Anthropometric measurements including height, weight, and 
head circumference were done for all FA patients. Analysis 
of the measurements compared to controls revealed a 
significant difference in the body weight (P = 0.02), and head 
circumference (P = 0.04). These measurements were repeated 
after treatment and revealed non significant improvement 
mainly in weight. After antioxidants intake, the FA patients 
showed an improvement of red blood cells, hemoglobin and 
platelets levels (the most significant improvement was in 
platelets, P = 0.02), while no change occurred in white blood 
cells count.
The second group (patients with DS) comprised of 12 males 
and three females with a ratio of 4:1. Their ages ranged from 
1 to 5 years; mean age was 3 (1.36) years. Positive parental 
consanguinity was observed in 46.6% of cases. There was no 
family history in DS patients. Congenital heart defect was 
found in 46.7% patients. Short stature was detected in 33.3% 
patients, microcephaly in 33.3% patients, and underweight 
in 20% patients. The body measurements in DS patients 
compared to the controls revealed a significant difference 
in the body weight (P < 0.01), height (P < 0.01), and head 
circumference (P < 0.01).
Table 2: Comparison of the clinical manifestations before 
and after antioxidants intake in the group I (FA)
Variable Group I before 
AOX (n=17)
Group I after 
AOX (n=17)

















1‑2 attacks/month One attack/3‑4 
months
Rate of blood 
transfusion
1‑2 times/month 0‑3 times/6 
months
AOX: Antioxidant
Figure 1: Comparison between malondialdehyde, total antioxidant 
capacity, and superoxide dismutase mean levels before and after 
antioxidants therapy in Fanconi anemia patients compared to controls
Figure 2: Comparison between diepoxybutane and DNA damage 
before and after antioxidants therapy in the group I (Fanconi anemia)
Figure 4: High power image of comet assay showing, (a) extensive 
DNA damage. (b) Less DNA damage after treatment
ba
Figure 3: (a) Partial metaphase with multiple chromosomal breaks 
giving triradial shapes of Fanconi anemia patients before starting 
the treatment. (b) Partial metaphases with decreased chromosomal 
breaks after treatment
ba
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Oxidative stress parameters in DS patients revealed 
significantly higher MDA (P < 0.01) and SOD (P = 0.01) 
levels, and non significantly different in TAC levels compared 
with controls [Figure 5]. A positive correlation was found 
between SOD and MDA in DS patients (r = 0.53 and P = 0.04, 
respectively). An improvement in oxidative stress parameters 
occurred after antioxidant administration with lowering of 
MDA (P < 0.01) and SOD levels (P < 0.05) state the actual 
P value and elevation in TAC levels (P < 0.01) [Figure 5]. 
DS patients showed more significantly higher DNA 
damage (P < 0.01) than controls. DNA damage levels 
improved (P < 0.01) non significantly after antioxidant 
administration [Table 3, Figure 6].
Anthropometric measurements including height, weight, and 
head circumference were done for all DS patients. Analysis of 
measurements revealed non‑significant improvement mainly 
in weight.
Comparison of the degree of improvement between FA and DS 
patients after antioxidant intake revealed more improvement 
in TAC in FA patients (P < 0.01), while a similar degree of 
improvement occurred in the rest of parameters in both FA and 
DS patients [Figures 7 and 8].
Discussion
Fanconi anemia and DS are two disorders that show 
chromosomal aberrations and increase cancer proneness. 
Understanding the relationship between oxidative stress and 
the manifestations and progression of these diseases is very 
crucial.
Figure 5: Comparison between malondialdehyde, total antioxidant 
capacity, and superoxide dismutase mean levels before and after 
antioxidants therapy between group II and controls
Figure 6: Comparison between DNA damage levels before and after 







Figure 7: Differences of oxidative stress parameters in the group I 
and II before and after taking antioxidants compared with the controls
Figure 8: Differences of DNA damage in the group I and II before and 
after taking antioxidants compared with the controls
Table 3: Comparison between the clinical manifestations 
before and after antioxidants intake in group II (down 
syndrome)
Variable Group II before 
AOX (n=15)
Group II after 
AOX (n=15)
Generalized hypotonia Present Improved
Developmental milestones Delayed Improved
Attacks of chest infection 1‑2 attacks/month One attack/ 
2‑3 months
AOX: Antioxidant
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The first group included in this study was diagnosed as FA 
by DEB test. Positive parental consanguinity was found in 
88.2% of the studied cases. Salem et al.,[23] reported a higher 
incidence of consanguinity (100%) among previously studied 
Egyptian FA patients. Other similarly affected family members 
were present in 58.8% of patients. These findings agree 
with the autosomal recessive inheritance. Online Mendelian 
Inheritance in Man[4] reviewed FA and confirmed an autosomal 
recessive trait in FA.
Anthropometric measurements including height, weight, 
and head circumference were assessed in the FA group 
of patients. Analysis of the measurements compared to 
controls revealed a significant difference in the body weight 
and head circumference, denoting the effect of FA on the 
growth of patients. Re-measurements of anthropometry after 
6 months of antioxidant supplement showed improvement 
in most of the patients’ body weight. Slight improvement 
in height and head circumference was also noticed. This 
improvement could be due to many factors affecting patient’s 
growth such as improved appetite, decreased frequencies of 
chest infections, decreased attacks of bleeding, and good 
compliance to treatment regimen. Pagano et al.,[24] suggested 
that antioxidants administration in FA patients aimed at 
delaying the clinical complications related to oxidative 
stress. In the present study, oxidative stress parameters in 
FA patients revealed significantly higher MDA levels than 
the controls; while SOD was non significantly lower than 
the controls. On the other hand, there was a non significant 
difference in TAC levels compared to controls. In addition, 
a negative correlation was present between SOD and MDA. 
These findings denote that these patients suffer from the effect 
of increased oxidative stress. These findings also point to a 
pro-oxidant state as a key event in the clinical phenotype 
of FA, providing mechanistic links between oxidative 
stress and disease progression. Pagano et al.,[24] reported 
significantly lower SOD activity in FA patients than in the 
controls. Petrovic et al.,[25] demonstrated the increase of MDA 
and strongly suggested that FA cells experience increased 
oxidative stress.
After antioxidants intake, the FA patients showed an 
improvement of red blood cells, hemoglobin and platelets 
levels (the most significant improvement was in platelets, while 
no change occurred in white blood cells count. Improving 
the oxidative stress status in patients may enhance the 
hematological cell synthesis and decrease apoptotic process 
of cells. Ponte et al.,[26] demonstrated that Vitamin E decreases 
the frequency of chromosomal damage and consequently 
ameliorating the hematological response.
Fanconi anemia group of patients showed higher DEB-induced 
chromosomal breakage, and more DNA damage compared to 
controls. This coincides with the findings of other researches 
who observed more DNA damage in FA patients than 
controls.[27,28]
Pagano et al.,[29] determined a direct association between 
oxidative DNA damage and chromosomal instability as 
hallmarks of FA phenotype with a significant increase in 
oxidative stress. In our study, a non significant correlation 
was found between oxidative stress and each of DEB-induced 
chromosomal breakage and DNA damage within FA group. 
This difference may be due to the smaller sample size of our 
study or may be due to the variation in the individual capacity 
of the patients to repair the DNA damage.
In the present study, comparing the results of DEB and DNA 
damage levels in FA patients before and after antioxidants 
administration, revealed improvement in the level of DEB 
induced chromosomal breakage, and DNA damage levels. 
Moreover, improvement in oxidative stress parameters 
occurred after antioxidant administration with significant 
lowering of MDA levels and significant elevation in TAC and 
SOD levels. Various studies regarding the administration of 
antioxidants to FA patients showed similar improvements of 
DNA damage and oxidative stress. Astley et al.,[30] concluded 
in their study that carotenoids and carotenoid-rich foods can 
influence DNA damage by counteracting oxidative stress. 
Similarly, Sacheck et al., and Bernard et al.,[28,31] published 
lower levels of DNA damage after ingestion of 100 mg 
Vitamin E/day for 12 weeks.
Pincheira et al.,[32] documented that Vitamin E decreased the 
frequency of chromosomal damage in FA cells. Collins[12] 
investigated the effect of carotene on oxidative DNA damage 
and found a negative correlation between total serum 
carotenoids and oxidized pyrimidines. On the contrary, 
Giovannelli et al.,[33] did not find a correlation between 
oxidative damaged DNA and antioxidant intake.
Tiano et al.,[34] reviewed the long-term supplementations 
with repeated ingestions of antioxidants in tablets or foods. 
They found improved DNA damage assessed by the comet 
or 8-OHdG measurement. They suggested that combined 
supplementation of Vitamin C and Vitamin E has been more 
successful than the single supplementation in showing a 
protective effect on oxidative damaged DNA.
The second group included 15 patients with trisomy 21. 
Congenital heart defect was found in 46.7% patients which 
was in agreement with the results of Weijerman et al.,[35] who 
found congenital heart defect in 43% of their DS cases.
Anthropometric measurements including height, weight, 
and head circumference for all DS patients revealed short 
stature in 33.3% patients, microcephaly in 33.3% patients 
and underweight in 20% patients. On the other hand, the 
body measurements in DS patients compared to the controls 
revealed a significant difference in the body weight, height, 
and head circumference. These results are in agreement with 
Chávez et al.,[36] who elucidated that patients with DS showed 
a significant decrease in height and weight compared to normal 
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individuals. These results are also matching with an interesting 
study done by Afifi et al.[37]
Oxidative stress parameters in DS patients revealed 
significantly higher MDA and SOD levels than the controls, 
while TAC levels were non significantly comparable to the 
controls. Furthermore, a positive correlation was found 
between SOD and MDA in DS patients. These findings 
confirmed that DS patients are suffering from oxidative stress 
which is partly due to the over-expression of the SOD gene on 
chromosome 21 in DS patients.[10] This is in agreement with 
Garaiová et al.,[38] who detected increased activity of SOD and 
higher MDA levels than the controls. Campos et al.,[39] proved 
that TAC was decreased in DS patients. Besides, TAC seems to 
provide more reliable information about the antioxidant status, 
at least in DS. In addition, Casado et al.,[40] reported a higher 
activity of SOD in blood cells of patients with DS compared 
to controls. They also documented a significant difference in 
serum concentration of MDA in DS patients.
In the present study, the DS group of patients showed more 
DNA damage than controls but no correlation was found 
between DNA damage and oxidative stress parameters. 
Many studies regarding increased DNA damage in DS are in 
agreement with the observations of the present study.[8,11,41]
Musalmah et al., (2006) and Ponte et al.,[25,42] reported an 
increase in DNA damage in lymphocytes of individuals with 
DS compared with controls, which was reduced by more than 
50% after the addition of Vitamin E to the cell culture. As 
Vitamin E is a powerful antioxidant, they hypothesized that 
the increased DNA damage in DS resulted from increased 
oxidative stress with a protective effect of Vitamin E on 
chromosomal damage.
An improvement in oxidative stress parameters occurred 
after antioxidant administration with lowering of MDA and 
SOD levels and elevation in TAC levels. Furthermore, DNA 
damage levels in DS patients improved after antioxidants 
intake. Ciaccio et al., Mustafa et al., Muchová et al.,[43-45] 
Several investigators evaluated the biochemical responses of 
a nutritional regimen supplemented with vitamins in children 
with DS and found improvement in the measurements of 
antioxidant enzymes and reactive oxygen species.
Comparing the degree of improvement of oxidative stress 
parameters after antioxidants intake between group I and II 
revealed significant improvement in TAC of group I compared 
to group II reflecting the more beneficial effect of antioxidants 
on FA patients. On the other hand, a similar degree of 
improvement was found in each of MDA and SOD in group I 
and II. In addition, comparing the degree of improvement of 
DNA damage after antioxidants intake between group I and 
II showed no difference. Lloret et al. and Ponte et al.,[2,25] 
published similar results and suggested that oxidative stress 
increases genomic instability.
Conclusion
Oxidative stress and DNA damage play a major role in 
FA and DS pathogenesis. Improvement in oxidative stress 
parameters and DNA damage occurred after the intake of 
antioxidants. Early administration of antioxidants should be 
recommended as a potential therapy for each of FA and DS 
patients with the ultimate goal of ameliorating life quality 
and life expectation.
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